NCT06151106 is a Phase 2 clinical trial of Chidamide combined with Duvillisib in Peripheral T Cell Lymphoma, sponsored by The First Affiliated Hospital of Xiamen University.

Who is sponsoring NCT06151106?

NCT06151106 is sponsored by The First Affiliated Hospital of Xiamen University.

What drugs are being tested in NCT06151106?

Interventions in NCT06151106: Chidamide combined with Duvillisib.

What condition does NCT06151106 study?

NCT06151106 studies Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma.

Is NCT06151106 still recruiting?

NCT06151106 is currently recruiting now. Last updated 19 February 2025.

Last reviewed 2025-02-19 · How we verify

NCT06151106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Recruiting now Phase 2 Last updated 19 February 2025

What this trial tests

Phase 2 trial testing Chidamide combined with Duvillisib in Peripheral T Cell Lymphoma in 33 participants. Currently enrolling.

Timeline

22 November 2023

Primary endpoint
31 December 2026

25 December 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Xiamen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	22 November 2023
Primary completion	31 December 2026
Estimated completion	25 December 2027
Sites	1 location across China

Drugs / interventions tested

Chidamide combined with Duvillisib — full drug profile →

Conditions studied

Peripheral T Cell Lymphoma — all drugs for Peripheral T Cell Lymphoma →
Relapsed Peripheral T-Cell Lymphoma — all drugs for Relapsed Peripheral T-Cell Lymphoma →
Refractory T-Cell Lymphoma — all drugs for Refractory T-Cell Lymphoma →

Sponsor

The First Affiliated Hospital of Xiamen University

Who can join

Adults 18 to 75, any sex, with Peripheral T Cell Lymphoma or Relapsed Peripheral T-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral T Cell Lymphoma

Currently open trials in the same condition.

NCT07414758 — Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy · Phase 3 · recruiting
NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07389616 — A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell · Phase 2, PHASE3 · recruiting
NCT07353840 — T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR · recruiting
NCT07253129 — Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort · recruiting

Other The First Affiliated Hospital of Xiamen University trials

Trials by the same sponsor.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06151106 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
Last refreshed: 19 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06151106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing